TD Asset Management
AVTX icon

TD Asset Management’s Avalo Therapeutics AVTX Stock Holding History

TD Asset Management’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$768K Buy
+51,408
New +$804K ﹤0.01% 1129

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

TD Asset Management's AVTX Position: Q1 2026 in Review

TD Asset Management opened a new position in Avalo Therapeutics (AVTX) in Q1 2026: 51,408 shares worth $768K. The stake represents ﹤0.01% of the portfolio and ranks #1129 among its holdings.

97 funds tracked by Wall St. Rank hold AVTX as of Q1 2026.

  • TD Asset Management held 51,408 shares of Avalo Therapeutics worth $768K as of Q1 2026.
  • Avalo Therapeutics was a new TD Asset Management position in Q1 2026.
  • Avalo Therapeutics made up ﹤0.01% of TD Asset Management's portfolio in Q1 2026, its #1129 holding.
  • 97 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2026.

Based on TD Asset Management's 13F filing for Q1 2026, filed 11 May 2026.